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OBJECTIVES We wished to determine the effect of post-infarct management strategy on event rates (death
or recurrent nonfatal myocardial infarction [MI]) in patients who evolved non–Q-wave MI
(NQMI) following thrombolytic therapy.
BACKGROUND Patients who evolve NQMI following thrombolytic therapy are often considered to be at high
risk and are frequently managed with routine early invasive testing despite a lack of data
supporting improved outcome.
METHODS The Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) study
included 115 patients who evolved NQMI following thrombolytic therapy. We compared the
event rates in patients randomized to routine early coronary angiography with those in
patients randomized to a conservative strategy of noninvasive functional assessment, with
angiography reserved for patients with spontaneous or induced ischemia.
RESULTS During an average follow-up of 23 months, 19 of 58 patients (33%) randomized to the
invasive management strategy died or suffered recurrent nonfatal MI, compared with 11 of 57
patients (19%) randomized to the conservative strategy (p 5 0.152). Equivalent numbers of
patients were subjected to revascularization (percutaneous transluminal coronary angioplasty
or coronary artery bypass graft). There were more deaths in the invasive management group
than in the conservative management group (11 vs. 2). Excess deaths could not be attributed
to periprocedural mortality.
CONCLUSIONS Overall event rates (death or recurrent nonfatal MI) are comparable with conservative and
invasive strategies in patients who evolve NQMI following thrombolytic therapy. Mortality
rate in patients managed conservatively is low (3.5%), and routine invasive management may
be associated with an increased risk of death. (J Am Coll Cardiol 2001;37:19–25) © 2001 by
the American College of Cardiology
The natural history of non–Q-wave myocardial infarction
(NQMI) following thrombolytic therapy is thought to be
similar to that of spontaneously occurring NQMI (1). Post
hoc analyses suggest that the prognosis of patients who
develop NQMI following lytic therapy is similar to that of
lytic treated patients overall and is not influenced by early
angiography and intervention. However, many centers rou-
tinely manage post-lytic NQMI patients with early coronary
angiography in the absence of data clearly supporting
See page 26
improved outcomes with this invasive approach (2,3). This
strategy is usually based on the assumption that evolution of
a NQMI following lytic therapy represents an incomplete
infarction, leaving myocardium in jeopardy that would be
protected by revascularization (4).
The Veterans Affairs Non–Q-Wave Infarction Strategies
In-Hospital (VANQWISH) trial (3) compared clinical
outcomes in a cohort of 920 NQMI patients randomized to
either a conservative post-myocardial infarction (MI) risk
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assessment strategy (noninvasive stress testing with coronary
angiography reserved for patients with spontaneous or
induced ischemia) or to routine predischarge coronary
angiography. Overall mortality during follow-up did not
differ significantly.
By study design, thrombolytic therapy was a predefined
stratifying variable for the randomization of NQMI patients
to the conservative (CON) or invasive (INV) management
strategy. In this report, we compare the clinical character-
istics and outcomes after randomization of the subgroup of
115 patients who developed NQMI after receiving
thrombolytic therapy with those of the remaining 805
VANQWISH patients with spontaneously occurring
NQMI. Based on previously reported similarities between
patients with post-lytic NQMI and spontaneously occurring
NQMI, we hypothesized that the CON and INV manage-
ment strategies would produce equivalent outcomes in the
subgroup of post lytic NQMI patients, as had been noted in
the overall VANQWISH cohort (3).
METHODS
Patient selection. Details of the VANQWISH trial design
and methodology have been published previously (5). Eli-
gible patients had a clinical presentation consistent with
evolving acute MI, MB-CK isoenzyme levels .1.5 times
the hospital upper limit of normal, and absence of new
abnormal Q waves (or R-waves for posterior infarction) on
serial electrocardiograms. At least one electrocardiogram
was obtained 48 h after admission to exclude late develop-
ment of Q waves, most of which (80%) occur within that
time period (6). Patients were excluded if they exhibited
significant co-morbidity or “very high risk” complications in
the coronary care unit (i.e., cardiogenic shock or severe heart
failure that persisted despite intravenous diuretics and/or
vasodilators; persistent or recurrent ischemia at rest despite
intensive medical therapy; symptomatic ventricular tachyar-
rhythmia) that posed clinical and/or ethical concerns for
inclusion in a randomized controlled trial.
Randomization procedure. Patients who met study entry
criteria and gave informed, written consent were random-
ized with the adaptive allocation (biased coin) procedure (7),
which maximized the probability of balance between strat-
egies by center and for each of five prognostic (stratifying)
variables: age (,60 years/.60 years), prior MI, infarct
location by electrocardiogram (anterior/nonanterior), entry
ST-segment depression and use of thrombolytic therapy.
Randomization typically occurred within 24 to 48 h after
infarct onset.
Invasive strategy. For patients assigned to the INV strat-
egy, coronary angiography was performed as the initial
diagnostic test soon after randomization. Subsequent deci-
sions regarding medical or revascularization therapy were
not dictated by the study but were made by the individual
investigator.
Conservative strategy. Patients randomized to the CON
strategy had a radionuclide ventriculogram to assess left
ventricular function as the initial noninvasive test, followed
by a predischarge symptom-limited (standard Bruce proto-
col) treadmill exercise test with thallium scintigraphy. Pa-
tients who were unable to achieve $5 METS of exercise
underwent thallium scintigraphy following standard proto-
col infusion of 0.56 mg/kg dipyridamole.
Coronary angiography with or without myocardial
revascularization was performed in patients randomized to
the CON strategy only if one or more of the following
criteria were met: 1) clinical criterion: recurrent post-
infarction angina with ischemic electrocardiographic
changes (.0.1 mV ST-segment deviation and/or T-wave
inversion in two or more contiguous leads); 2) exercise
electrocardiographic criterion: $2 mm ST-segment depres-
sion during peak exercise; and 3) “high-risk” thallium pattern:
redistribution defects in two or more different vascular
regions, or one redistribution defect with increased lung-to-
heart ratio of thallium uptake.
Decisions to perform myocardial revascularization in
patients with objective evidence of ischemia were made by
the site investigator.
Medical therapy. Whenever safe and appropriate, all study
patients received enteric-coated aspirin 325 mg/day and
long-acting Diltiazem 180 mg/day to 300 mg/day, based on
reports supporting this therapy as secondary prevention
following NQMI (8). Patients could also receive any other
medical therapy considered to be standard care during the
early course of hospitalization, including nitroglycerin, an-
giotensin converting-enzyme inhibitors, beta-blockers or
dose-adjusted intravenous heparin.
Follow-up and end points. Patients were seen one month
following discharge, and at three-month intervals until trial
termination. The primary end point of the trial was all-
cause mortality or recurrent nonfatal MI during a minimal
12-month follow-up period. All-cause mortality was a
secondary end point. Patients were followed for a mean of
23 months.
Statistical analysis. Categorical baseline characteristics be-
tween groups were analyzed using Pearson’s chi-square test,
whereas continuous outcomes were tested with Student t-
test. Kaplan-Meier (9) curves were used to describe the
event and mortality distributions between the thrombolytic
Abbreviations and Acronyms
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therapy groups. Where appropriate, hazard ratios were
adjusted for imbalanced baseline covariates using the Cox
proportional-hazards regression model (10).
RESULTS
Characteristics of the study population and comparison
of post-lytic to spontaneous NQMI patient subgroups.
Of the 920 randomized patients from the 17 study sites, 115
(12.5%) received thrombolytic therapy. Their clinical char-
acteristics are compared with those of the remaining 805
spontaneously occurring NQMI patients in Table 1. The
post-lytic patients were slightly younger and had a lower
prevalence of diabetes mellitus, hypertension, peripheral
vascular disease and current smoking than the patients with
spontaneously occurring NQMI.
Table 2 compares results of noninvasive and invasive
studies performed in patients with post-thrombolytic and
spontaneous NQMI. Left ventricular ejection fraction
(LVEF) was slightly higher in the post-lytic patients; and a
smaller percent had LVEF ,35%. Post-infarct thallium
studies, performed primarily in patients randomized to the
CON arm, showed a similar prevalence of high-risk pat-
terns (as described in the Methods section).
A similar percentage of patients in the post-lytic and
spontaneous NQMI subgroups underwent coronary angiog-
raphy before discharge. In addition to those randomized to
the INV arm, 18% of the post-lytic and 25% of the
spontaneous NQMI patients randomized to the CON arm
underwent protocol-based coronary angiography during the
index hospitalization because of high-risk clinical or non-
Figure 1. Kaplan-Meier analysis of the probability of event-free survival in
patients who developed non–Q-wave myocardial infarction following
thrombolytic therapy (solid line) or spontaneously, i.e., in the absence of
thrombolytic therapy (dashed line). The events included in this analysis
were death and recurrent nonfatal myocardial infarction. The Cox
proportional-hazards ratio for post-thrombolytic as compared with spon-
taneous non–Q-wave myocardial infarction was 0.92 (95% confidence
interval, 0.6 to 1.40), adjusted for age, history of diabetes and prior
myocardial infarction, and maximum creatine kinase level.
Figure 2. Kaplan-Meier analysis of the probability of survival in patients
who developed non–Q-wave myocardial infarction following thrombolytic
therapy (solid line) or spontaneously, i.e., in the absence of thrombolytic
therapy (dashed line). Death from any cause was included in this analysis.
The Cox proportional-hazards ratio for post-thrombolytic as compared
with spontaneous non–Q-wave myocardial infarction was 0.65 (95%
confidence interval, 0.33 to 1.27), adjusted for age, history of diabetes, prior
myocardial infarction, peripheral vascular disease and maximum creatine
kinase level.
Table 1. Comparison of Clinical Characteristics of Post-
Thrombolytic and Spontaneous NQMI Patients
Post-lytic
(n 5 115)
N (%)
Spontaneous
(n 5 805)
N (%) p Value
Age (yrs) 59 6 10 62 6 10 0.003
DM (%) 15 (13%) 225 (28%) , 0.001
HTN (%) 41 (36%) 457 (57%) , 0.001
PVD (%) 12 (10%) 154 (19%) 0.035
Current smoker (%) 44 (38%) 477 (59%) , 0.001
ST elevation (%) 97 (84%) 175 (22%) , 0.001
Mean CK 1377 6 1277 618 6 482 , 0.001
Prior MI on ECG 33 (29%) 363 (45%) , 0.001
Anterior location (%) 71 (62%) 321 (40%) , 0.001
HR $ 80 bpm (%) 46 (40%) 351 (44%) 0.515
QRS $ 100 ms (%) 42 (37%) 351 (44%) 0.174
CK 5 creatine kinase; DM 5 diabetes mellitus; ECG 5 electrocardiogram; HR 5
heart rate; HTN 5 hypertension; NQMI 5 non–Q-wave myocardial infarction;
MI 5 myocardial infarction; PVD 5 peripheral vascular disease.
Table 2. Results of Noninvasive and Invasive Studies and
Revascularization Procedures in Post-Thrombolytic and
Spontaneous NQMI Patients
Post-lytic
(n 5 115)
N (%)
Spontaneous
(n 5 805)
N (%) p Value
LVEF 54 6 13 51 6 15 0.037
Not measured 9 (8) 80 (10) 0.008
EF # 35% 6 (5) 123 (15)
Thallium scan 56 (49) 372 (46)
High risk* 11 (20) 116 (31) 0.108
Coronary angiogram 64 (56) 481 (60)
Nonsignificant 1 (2) 24 (5)
1-vd 23 (36) 88 (18)
2-vd 19 (30) 111 (23)
3-vd 20 (31) 202 (42)
Left main 6 $1 vd 1 (2) 48 (10)
Unknown 0 (0) 7 (1)
Revasc 43 (37) 313 (39) 0.838
PTCA 31 (27) 143 (18) 0.030
CABG 16 (14) 187 (23) 0.030
*High risk was defined as redistribution defects in two or more vascular regions or one
or more redistribution defects with increased lung-to-heart uptake ratio of thallium.
CABG 5 coronary artery bypass graft; EF 5 ejection fraction; LVEF 5 left
ventricular ejection fraction; NQMI 5 non–Q-wave myocardial infarction; PTCA 5
percutaneous transluminal coronary angioplasty; Revasc 5 revascularization; vd 5
vessel disease.
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invasive test indicators. Distribution of coronary artery
lesions was similar in the two groups, although there was a
trend toward less severe disease in the post-lytic group,
which had a higher prevalence of single-vessel disease and a
lower prevalence of three-vessel disease.
Patients were equally likely to undergo revascularization
following post-lytic or spontaneous NQMI, but post-lytic
patients were more likely to undergo PTCA and less likely
to undergo CABG, probably in concert with their higher
prevalence of single-vessel disease.
Comparison of outcomes in post-lytic versus spontane-
ous NQMI subgroups. Figures 1 and 2 show Kaplan–
Meier analyses of the probability of event-free survival
(Fig. 1) and survival (Fig. 2) in post-lytic and spontaneously
occurring NQMI during the 12 to 44 month follow-up
period. Neither the survival rate nor the event-free survival
rate differed significantly over the 23-month follow-up
period. The proportion of patients with combined end
points and the proportion of patients who died were similar
(Table 3).
Comparison of outcomes in post-lytic NQMI patients
randomized to CON or INV management strategy.
Table 4 compares the clinical characteristics of the 115
post-lytic NQMI patients randomized to the CON or the
INV management strategy, indicating they were closely
matched with respect to age, risk factors, and ECG variables.
Figures 3 and 4 compare outcomes in the 115 post-lytic
NQMI patients randomized to the CON or INV strategy.
The difference between the cumulative rates of death or
recurrent MI during long-term follow-up did not reach
statistical significance. However, cumulative rate of death
was significantly lower in the CON group than in the INV
group (p 5 0.014).
Comparison of outcomes in patients according to man-
agement strategy. Table 5 compares clinical outcomes
according to assigned management strategy in the post-lytic
and spontaneous NQMI patients. Among all four sub-
groups, the most strikingly different outcome was the low
(3.5%) mortality rate in the post-lytic NQMI patients
randomized to the CON strategy.
Table 6 shows the revascularization procedures per-
formed during follow-up in the post-lytic NQMI patients
Figure 3. Kaplan-Meier analysis of the probability of event-free survival
according to strategy group in patients who developed non–Q-wave
myocardial infarction following thrombolytic therapy. The events included
in this analysis were death and recurrent nonfatal myocardial infarction.
The Cox proportional-hazards ratio for the conservative (ischemia-guided)
strategy as compared with the routine invasive strategy was 0.58 (95%
confidence interval, 0.28 to 1.28).
Figure 4. Kaplan-Meier analysis of the probability of survival according to
strategy group in patients who developed non–Q-wave myocardial infarc-
tion following thrombolytic therapy. Death from any cause was included in
the analysis. The Cox proportional-hazards ratio for the conservative
(ischemia-guided) strategy as compared with the routine invasive strategy
was 0.18 (95% confidence interval, 0.04 to 0.83).
Table 3. Clinical Outcomes in Post-lytic and Spontaneous
NQMI Patients
Post-lytic
(n 5 115)
N (%)
Spontaneous
(n 5 805)
N (%) p Value
Death or recurrent MI 30 (26%) 231 (29%) 0.638
Death 13 (11%) 126 (16%) 0.281
MI 5 myocardial infarction; NQMI 5 non–Q-wave myocardial infarction.
Table 4. Clinical Characteristics of Post-Lytic NQMI Patients
Randomized to the Invasive (INV) or Conservative
(CON) Strategy
INV
(n 5 58)
N (%)
CON
(n 5 57)
N (%) p Value
Age (yrs) 59 6 9 58 6 10 0.481
DM 8 (14%) 7 (12%)
HTN 25 (43%) 16 (28%) 0.119
PVD 7 (12%) 5 (9%) 0.760
Current smoker 22 (38%) 22 (39%) 0.906
ST elevation 48 (83%) 49 (86%) 0.829
Mean CK 1438 6 1282 1315 6 1280 0.606
Prior MI on ECG 16 (28%) 17 (30%) 0.953
Anterior location 36 (62%) 35 (61%) 0.906
HR 28 (48%) 18 (32%) 0.102
QRS 23 (40%) 19 (33%) 0.610
LVEF 57 6 11 52 6 14 0.058
Not measured 7 (12%) 2 (4%)
EF # 35% 1 (2%) 5 (9%)
*LVEF was obtained by different methods in the INV and CON groups. The
majority of patients in the INV group had LVEF measured by contrast ventriculog-
raphy; the majority in the CON group had radionuclide ventriculography.
CK 5 creatine kinase; DM 5 diabetes mellitus; ECG 5 electrocardiogram; EF 5
ejection fraction; HR 5 heart rate; HTN 5 hypertension; LVEF 5 left ventricular
ejection fraction; MI 5 myocardial infarction; NQMI 5 non–Q-wave myocardial
infarction; PVD 5 peripheral vascular disease.
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randomized to the two strategies. More revascularization
procedures were performed in patients randomized to the
INV strategy, primarily because of a significantly greater
number of patients undergoing PTCA.
The reported causes of death and procedures performed
in the post-lytic NQMI patients are shown in Table 7.
Approximately half the deaths in the INV group occurred
within six months of NQMI. In contrast, the two deaths in
the CON group (both noncardiac) occurred more than six
months after NQMI. Two patients in the INV group died
prior to angiography. None died within 24 h of coronary
angiography. None of the patients who died underwent
PTCA. Of three patients who had CABG, none were
recorded as postoperative deaths.
DISCUSSION
As we have reported elsewhere, the VANQWISH study
demonstrated no benefit associated with an early invasive as
compared with a conservative, ischemia-guided post infarct
management strategy in a large (n 5 920) cohort of patients
with NQMI, the majority of whom had spontaneously
occurring infarcts (3). The subgroup of 115 post-lytic
NQMI patients also showed no benefit from invasive as
compared with conservative management. Of particular
note is the very low mortality rate in the post-lytic patients
treated conservatively (3.5%).
The increased number of deaths associated with the INV
management strategy (11 vs. 2) is of uncertain significance
given the small number of events (Table 7). The apparent
excess deaths in the INV group occurred largely in the first
six months after randomization but could not be attributed
to different clinical characteristics or ECG variables or to an
increased surgical or procedural mortality rate. Differences
in severity of underlying disease cannot be excluded; the
number of patients in the CON group who underwent
protocol-based coronary angiography (10/57) was too small
too allow meaningful comparisons of the distribution of
coronary lesions between the INV and CON groups.
Our study showed no significant outcome differences
between patients whose NQMI followed thrombolytic ther-
apy and those with spontaneously occurring NQMI. This
was also implied in the TIMI IIIB study (11), in which
event rates at one year were similar in the post-lytic and
placebo-treated NQMI groups, the latter group being
comparable to the spontaneously occurring NQMI patients
in our study.
Few major trials have specifically addressed the issue of
appropriate management strategies in NQMI following
thrombolytic therapy. The TIMI II trial provided a post hoc
analysis of patients who evolved NQMI following throm-
bolytic therapy (12). At 42 days follow-up, event rates were
not significantly different in those treated conservatively or
invasively. The TIMI IIIB trial also compared the outcomes
of invasive and conservative strategies similar to those used
in the present study (2,11). Of the 477 patients with
NQMI, neither mortality rate nor rate of recurrent nonfatal
MI were different among patients randomized to each
strategy.
A significant difference between the TIMI IIIB trial and
the present study is that the crossover rate from the CON to
the INV arm was much higher in TIMI IIIB (64%). The
relatively low rate of protocol-driven angiography in the
CON group (23%), which signified that the majority of
patients remained within their assigned treatment group,
supports the validity of the comparison between the two
treatment arms and strengthens our conclusion that there is
no benefit to a routine early invasive strategy in this
subgroup of patients.
Study limitations. By study design, patients with obvious
indications for early revascularization, such as hemodynamic
instability or ongoing medically refractory chest pain, were
excluded from randomization. As such, the study popula-
tion consisted of NQMI patients who did not have obvious
urgent indications for invasive study within the first 24 to
48 h after diagnosis of NQMI. However, this represented
only 10% of the protocol-eligible patients in the overall
VANQWISH cohort (3). Because we did not exclude
patients with anterior location of MI, age .60 years or low
left ventricular ejection fraction, this study included a repre-
Table 5. Outcomes of Post-lytic and Spontaneous NQMI Patients According to Assessment Strategy
Post-lytic Spontaneous
INV
(n 5 58)
N (%)
CON
(n 5 57)
N (%)
p
Value
INV
(n 5 404)
N (%)
CON
(n 5 401)
N (%)
p
Value
Death/MI 19 (33) 11 (19) 0.152 119 (29) 112 (28) 0.689
Death 11 (19) 2 (3.5) 0.020 69 (17) 57 (14) 0.307
CON 5 conservative management strategy; Death/MI 5 death or nonfatal myocardial infarction; INV 5 invasive management strategy; NQMI 5 non–Q-wave myocardial
infarction.
Table 6. Revascularization Procedures in Post-Lytic NQMI
Patients Randomized to Invasive (INV) or Conservative (CON)
Management Strategies
INV
(n 5 58)
N (%)
CON
(n 5 57)
N (%) p Value
Revasc 27 (47%) 16 (28%) 0.064
PTCA 21 (36%) 10 (18%) 0.041
CABG 7 (12%) 9 (16%) 0.759
CABG 5 coronary artery bypass graft; NQMI 5 non–Q-wave myocardial infarction;
PTCA 5 percutaneous transluminal coronary angioplasty; Revasc 5 revascularization.
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sentative sample of NQMI patients, many of whom had
features known to confer increased risk of poor outcome and
considered to be indications for early invasive management.
In summary, a strategy of conservative, ischemia-guided
management of patients who evolve NQMI following
thrombolytic therapy appears to be safe and effective.
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Crawford, M. Holland, K. Wagoner; Cincinnati—L. Wex-
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Carbajal, R. Kanefield; Gainesville, Florida—C. Pepine, J.
Green, Jr., M. Limacher, E. Handberg Thurmond, N.
Davis; Hines, Illinois—M. Hwang, S. Lemoine; Hous-
ton—A. Blaustein, C. Rowe; Lexington, Kentucky—C.
Chasen, P. Frazier; Little Rock, Arkansas—M. Murphy, J.
Doherty, E. Smith, III, J. Calkins, Jr., A. Bierle; Loma
Linda, California—D. Ferry, A. Jacobson, G. Frivold, K.
Okubo; Nashville—R. Smith, S. Levine, R. Bruce; Palo
Alto, California—J. Giacomini, C. Stepp; Richmond, Vir-
ginia—R. Jesse, A. Minisi, C. Murphy; San Antonio,
Texas—R. O’Rourke, A. Jain, C. Patterson; San Diego,
California—A. Maisel; Seattle—K. Lehmann, J. Caldwell,
S. Ferris; St. Louis—H. Stratmann, L. Younis, L. Conwill;
Tampa, Florida—R. Zoble, G. Cintron, J. Sullebarger, J.
Umberger; Cooperative Studies Program Coordinating
Center (Palo Alto, California): P. Lavori (chief), D. Bloch,
B. Chow, M. Iwane, R. Thomas, A. Busette, L. Sheridan,
R. Yezzi, S. Jones, J. King, K. Small; Cooperative Studies
Program Clinical Research Pharmacy Coordinating Center
(Albuquerque): C. Haakenson, M. Miller, L. Guidarelli, L.
Vasquez, F. Chacon, C. Tripp, G. Garcia, J. Price; Coop-
erative Studies Program Central Office: P. Huang, Wash-
ington, D.C., and J. Gold, Boston; Planning Committee: J.
Abrams, University of New Mexico, Albuquerque; T. Big-
ger, Columbia University, New York; P. Carson, George-
town University, Washington, D.C.; R. Kleiger, Jewish
Hospital of St. Louis; J. Leppo, University of Massachu-
setts, Worcester; M. Moskowitz, Boston University; M.
Smith Veterans Affairs Medical Center, Manchester, New
Hampshire: M. Hlatky, Stanford University, Stanford, Cal-
ifornia; R. Thomas Veterans Affairs Medical Center, Palo
Alto, California; End-Points Committee: C. Cannon
(chairman), Brigham and Women’s Hospital, Boston; K.
Eagle, University of Michigan Medical Center, Ann Arbor;
D. Losordo, St. Elizabeth’s Hospital, Boston; Data Moni-
toring Board: B. Pitt (chairman), University of Michigan
Medical Center, Ann Arbor; M. Moskowitz, University
Hospital, Boston; A. Moss, University of Rochester Med-
ical Center, Rochester, New York; R. DeBusk, Stanford
University School of Medicine, Palo Alto, California; S.
Azen, University of Southern California, Los Angeles; R.
Schlant, Emory University School of Medicine, Atlanta; J.
Wittes, Statistics Collaborative, Washington, D.C.; Core
Laboratories: R. Kleiger, Electrocardiography Core Labo-
ratory, Jewish Hospital, Washington University School of
Medicine, St. Louis; J. Leppo, Nuclear Cardiology Quality
Assessment Laboratory, University of Massachusetts Med-
ical Center, Worcester; R. Kerensky, Coronary Angiogra-
phy Quality Assessment Laboratory, University of Florida,
Gainesville.
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